Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

IFPA urges WHO to act on new insights on psoriasis to help millions of psoriasis patients

October 29 is World Psoriasis Day. Conceived by patients for patients, World Psoriasis Day is a truly global event focusing on the burden of living with psoriasis. There are more than 125 million people with psoriasis/psoriatic arthritis in the world. Psoriasis is a severe chronic inflammatory disease that effects all ages, genders, races and ethnicities.

28 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

The CE Marked HairDX Genetic Test for Hair Loss launched in Europe

The HairDX Genetic Test for Hair Loss, the world’s first genetic baldness (Androgenetic Alopecia) test, is now available as a CE Marked product under the European In Vitro Diagnostic Directive.

8 Oct 2009

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Women with psoriasis and psoriatic arthritis are markedly more likely than men to suffer from the emotional and psychological effects of the diseases, according to survey data released by the National Psoriasis Foundation today.

1 Oct 2009

Symposium on genetics of psoriasis and psoriatic arthritis to be held

A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol - Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany.

24 Sep 2009

Comprehensive and practical overview of psoriasis

Treatments for psoriasis often present a therapeutic challenge to physicians because, besides affecting the skin, psoriasis may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases).

22 Sep 2009

PsoriasisDX Genetic Test for Psoriatic arthritis launched

The first genetic test for Psoriatic arthritis (PsA) is being launched today by PsoriasisDX, LLC, a subsidiary of molecular dermatology research and development innovator PharmaGenoma, Inc. PsA is a progressive irreversible joint disease associated with psoriasis. It is estimated that 20% to 40% of psoriasis patients will eventually develop PsA.

16 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

Psoriasis Walk organized to support the research and education programs of Psoriasis Cure Now

The first-ever New Jersey Psoriasis Walk will take place in Paramus this Saturday, September 12, 2009, at beautiful Van Saun Park. The walk, to support the research and education programs of the nonprofit Psoriasis Cure Now, will include entertainment, information booths on psoriasis treatments, and a chance to meet and learn from others living with psoriasis and psoriatic arthritis. Janine Natoli of Little Falls is volunteer Chair of the NJ Psoriasis Walk, on the Web at http://www.PsoriasisWalkNJ.org.

9 Sep 2009

Fashion show to help raise public awareness of psoriasis

Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City.

3 Sep 2009

Fernando Pisani and 24 hockey players helped raise funds and awareness about Crohn's disease and ulcerative colitis

The spirit of giving back was as strong as ever this weekend at the first ever Score for Colitis & Crohn's event, which raised $20,000 for four gastrointestinal and digestive disease patient organizations from across the country. The Score for Colitis & Crohn's initiative, which took place at the West Edmonton Mall's Ice Palace on Saturday, August 29th, featured Fernando Pisani of the Edmonton Oilers and 24 aspiring young hockey enthusiasts who were all on hand to help raise funds and awareness about Crohn's disease and ulcerative colitis, the latter of which Pisani was diagnosed with in 2007.

31 Aug 2009

HLA-Cw*0602 gene variation detected as a high risk for psoriasis

A specific genetic region that has been increasingly identified as the strongest genetic link to psoriasis has an even more significant role in the chronic skin disease than has been suspected, University of Utah medical researchers show in a new study.

27 Aug 2009

Psoriasis sufferers at risk for other medical conditions

Emerging research reveals that people with psoriasis are at risk for developing other serious medical conditions including heart disease, diabetes and obesity. According to a new study by the National Psoriasis Foundation, of 5,000 people with psoriasis, nearly two-thirds report having at least one other critical health problem.

6 Aug 2009

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

13 Apr 2009